NCT06125223View on ClinicalTrials.gov

PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma

Not yet recruitingOBSERVATIONAL
Enrollment

45

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2026

Conditions
Squamous Cell Carcinoma of Head and NeckNeoadjuvant TherapyImmunotherapy
All Listed Sponsors
lead

Xijing Hospital

OTHER

NCT06125223 - PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma | Biotech Hunter | Biotech Hunter